Abstract | OBJECTIVE: METHOD: In this pilot study, the authors examined the efficacy of xanomeline on clinical outcomes in subjects with schizophrenia (N=20) utilizing a double-blind, placebo-controlled, 4-week treatment design. Outcome measures included the Positive and Negative Syndrome Scale (PANSS) for schizophrenia, the Brief Psychiatric Rating Scale (BPRS), the Clinical Global Impression (CGI) scale, and a test battery designed to measure cognitive function in patients with schizophrenia. RESULTS: Subjects treated with xanomeline did significantly better than subjects in the placebo group on total BPRS scores and total PANSS scores. In the cognitive test battery, subjects in the xanomeline group showed improvements most robustly in measures of verbal learning and short-term memory function. CONCLUSIONS:
|
Authors | Anantha Shekhar, William Z Potter, Jeffrey Lightfoot, John Lienemann, Sanjay Dubé, Craig Mallinckrodt, Frank P Bymaster, David L McKinzie, Christian C Felder |
Journal | The American journal of psychiatry
(Am J Psychiatry)
Vol. 165
Issue 8
Pg. 1033-9
(Aug 2008)
ISSN: 1535-7228 [Electronic] United States |
PMID | 18593778
(Publication Type: Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Muscarinic Agonists
- Pyridines
- Receptors, Cholinergic
- Receptors, Muscarinic
- Thiadiazoles
- xanomeline
|
Topics |
- Adolescent
- Adult
- Affect
- Brief Psychiatric Rating Scale
- Cognition Disorders
(diagnosis, epidemiology)
- Demography
- Double-Blind Method
- Female
- Humans
- Male
- Middle Aged
- Muscarinic Agonists
(adverse effects, pharmacology, therapeutic use)
- Neuropsychological Tests
- Pyridines
(adverse effects, pharmacology, therapeutic use)
- Receptors, Cholinergic
(drug effects)
- Receptors, Muscarinic
(drug effects)
- Schizophrenia
(drug therapy, epidemiology)
- Severity of Illness Index
- Thiadiazoles
(adverse effects, pharmacology, therapeutic use)
|